Relationship of redundant Th17 cells and IL-17A, but not IL-17 F, with the severity of obstructive sleep apnoea/hypopnoea syndrome (OSAHS)

BMC Pulmonary Medicine

Jianying Zhou¹  Guohua Lu¹  Qing Wang¹  Pei Zhang¹  Shanni Ma¹  Zhijie Pan¹  Hequan Li¹  Lin Ying¹ 

[1] Department of Respiratory Diseases, First Affiliated Hospital of Zhejiang, University School of Medicine, Zhejiang University, Zhejiang, P.R. China

关键词: Inflammation;    Pulmonary arterial hypertension;    IL-17;    Th17 cell;    Obstructive sleep apnea hypopnea syndrome;   

Others  :  862915
DOI  :  10.1186/1471-2466-14-84

 received in 2013-10-18, accepted in 2014-05-08,  发布年份 2014

【 摘 要 】

Background

The pathogenesis of obstructive sleep apnoea/hypopnoea syndrome (OSAHS), a highly prevalent disease, is not completely understood. The purpose of this study was to investigate the contributions of Th17 cells and the Th17-associated cytokines IL-17A and IL-17 F to OSAHS.

Methods

46 male patients with a clinical suspicion of OSAHS were enrolled and divided into four groups based on their polysomnography results: controls and mild, moderate, and severe OSAHS. The serum levels of IL-17A and IL-17 F were determined by enzyme linked immunosorbent assay (ELISA), pulmonary arterial pressure (PAP) was determined by echocardiography, and Th17 cell frequencies in peripheral blood were measured by flow cytometry.

Results

Serum IL-17A levels in the severe group were elevated (median value: control group 0.89 pg/ml, mild OSAHS 1.02 pg/ml, moderate OSAHS 1.18 pg/ml, and severe OSAHS 1.62 pg/ml; p < 0.05) and positively correlated with AHI (r = 0.52, p < 0.05) but negatively related to the mean O₂ saturation and lowest O₂ saturation (r = −0.349, p < 0.05; and r = −0.336, p < 0.05, respectively). Although the frequencies of Th17 cells in the OSAHS groups were higher than that in the control group, these differences were not significant (p = 0.275). Pulmonary arterial hypertension was not present in our patients as the median PAP of the normal control and the mild, moderate, and severe OSAHS groups were 26, 27.5, 24.5, and 25.5 mmHg, respectively (p = 0.676).

Conclusion

IL-17A may be involved in the pathogenesis of OSAHS and may represent a target for therapeutic intervention.

【 授权许可】

   
2014 Ying et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Lurie A: Obstructive sleep apnea in adults: epidemiology, clinical presentation, and treatment options. Adv Cardiol 2011, l46:1-42.
• [2]Peker Y, Hedner J, Kraiczi H, Löth S: Respiratory disturbance index: an independent predictor of mortality in coronary artery disease. Am J Respir Crit Care Med 2000, 162:81-86.
• [3]Kokturk O, Ciftci TU, Mollarecep E, Ciftci B: Elevated Creactive protein levels and increased cardiovascular risk in patients with obstructive sleep apnea syndrome. Int Heart J 2005, 46:801-809.
• [4]Zamarrón C1, Valdés Cuadrado L, Alvarez-Sala R: Pathophysiologic mechanisms of cardiovascular disease in obstructive sleep apnea syndrome. Pulm Med 2013. 521087
• [5]Dyugovskaya L, Lavie P, Hirsh M, Lavie L: Activated CD8+ T-lymphocytes in obstructive sleep apnoea. Eur Respir J 2005, 25:820-828.
• [6]Tan HL, Gozal D, Wang Y, Bandla HP, Bhattacharjee R, Kulkarni R, Kheirandish-Gozal L: Alterations in circulating T-cell lymphocyte populations in children with obstructive sleep apnea. Sleep 2013, 36:913-922.
• [7]Bettelli E, Oukka M, Kuchroo VK: T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007, l8:345-350.
• [8]Miossec P, Korn T, Kuchroo VK: Interleukin-17 and type 17 helper T cells. N Engl J Med 2009, 361:888-898.
• [9]Maddur MS, Miossec P, Kaveri SV, Bayry J: Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol 2012, 181:8-18.
• [10]Sade K, Fishman G, Shmuel K, Ari DR, Sheila L: Expression of Th17 and Treg lymphocyte Subsets in hypertrophied adenoids of children and its clinical significance. Immunol Invest 2011, 40:657-666.
• [11]Katz ES, D’Ambrosio CM: Pathophysiology of pediatric obstructive sleep apnea. Proc Am Thorac Soc 2008, 5:253-262.
• [12]Epstein LJ, Kristo D, Strollo PJ Jr, Friedman N, Malhotra A, Patil SP, Ramar K, Rogers R, Schwab RJ, Weaver EM, Weinstein MD: Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med 2009, 5:263-276.
• [13]Nakanishi N1, European Society of Cardiology,European Respiratory Society: 2009 ESC/ERS pulmonary hypertension guidelines and connective tissue disease. Allergol Int 2011, 60:419-424.
• [14]Umur H, Israel R: Inflammation and obstructive sleep apnea syndrome pathogenesis: a working hypothesis. Respiration 2003, 70:665-671.
• [15]El-Solh AA, Mador MJ, Sikka P, Dhillon RS, Amsterdam D, Grant BJ: Adhesion molecules in patients with coronary artery disease and moderate-to-severe obstructive sleep apnea. Chest 2002, 121:1541-1547.
• [16]Alam I, Lewis K, Stephens JW, Baxter JN: Obesity, metabolic syndrome and sleep apnoea: all pro-inflammatory states. Obes Rev 2007, 8:119-127.
• [17]Punjabi NM, Beamer BA: C-reactive protein is associated with sleep disordered breathing independent of adiposity. Sleep 2007, 30:29-34.
• [18]Umur H, Israel R: Inflammation and obstructive sleep apnea syndrome:how many ways do I look at them? Chest 2004, 126:1-2.
• [19]Teramoto S, Yamamoto H, Ouchi Y: Increased plasma interleukin-6 is associated with the pathogenesis of obstructive sleep apnea syndrome. Chest 2004, 125:1964-1965.
• [20]Stockinger B, Veldhoen M: Differentiation and function of Th17 T cells. Curr Opin Immunol 2007, 19:281-286.
• [21]Zhu J, Paul WE: Heterogeneity and plasticity of T helper cells. Cell Res 2010, 20:4-12.
• [22]Anderson ME Jr1, Buchwald ZS, Ko J, Aurora R, Sanford T: Patients with pediatric obstructive sleep apnea show altered T-Cell populations with a dominant TH17 profile. Otolaryngol Head Neck Surg 2014. Jan 31. [Epub ahead of print]
• [23]Arias MA, García-Río F, Alonso-Fernández A, Martínez I, Villamor J: Pulmonary hypertension in obstructive sleep apnoea: effects of continuous positive airway pressure: A randomized, controlled cross-over study. Eur Heart J 2006, 27:1106-1113.
• [24]Alchanatis M, Tourkohoriti G, Kakouros S, Kosmas E, Podaras S, Jordanoglou JB: Daytime pulmonary hypertension in patients with obstructive sleep apnea: the effect of continuous positive airway pressure on pulmonary hemodynamics. Respiration 2001, 68:566-572.
• [25]Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G: Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009, 34:1219-1263.
• [26]Stenmark KR, Fagan KA, Frid MG: Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res 2006, 99:675-691.
• [27]Adegunsoye A, Ramachandran S: Etiopathogenetic mechanisms of pulmonary hypertension in sleep-related breathing disorders. Pulm Med 2012. 273591